^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:ProstAtak (aglatimagene besadenovec) (Gene transference, Thymidine kinase stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BioSpace
    Title:

    Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

    Published date:
    12/12/2023
    Excerpt:
    Candel Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.
    Secondary therapy:
    valacyclovir